-
Product Insights
NewCoagulation Factor XI – Drugs In Development, 2024
The Coagulation Factor XI pipeline drugs market research report outlays comprehensive information on the Coagulation Factor XI targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Hematological Disorders, Genito Urinary System, and Central Nervous System which include indications of Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Hemophilia C (Factor XI Deficiency), End-Stage Kidney Disease (End-Stage Renal Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EC-313 in Endometriosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EC-313 in Endometriosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EC-313 in Endometriosis Drug Details: EC-313 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EC-313 in Uterine Leiomyoma (Uterine Fibroids)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EC-313 in Uterine Leiomyoma (Uterine Fibroids) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EC-313 in Uterine Leiomyoma (Uterine Fibroids) Drug Details: EC-313...
-
Product Insights
NewGATT Technologies BV Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our GATT Technologies BV Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. GATT Technologies BV (GATT Technologies) is a medical technology company which develops synthetic surgical hemostat and sealant products that control severe bleeding. Its product pipeline includes GATT-Patch for controlling excessive bleeding; GATT-Tape for blocking intestinal anastomotic leakage; GATT-Powder, a one syringe solution for preventing uncontrolled bleeding and anti-coagulated blood; and GATT-Spray, a sturdy adhesive elastic sealant in general surgery....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APAC in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APAC in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APAC in Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APAC in Critical Limb Ischemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APAC in Critical Limb Ischemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APAC in Critical Limb Ischemia Drug Details: Recombinant protein is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-595 in Primary Immune Deficiency (PID)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-595 in Primary Immune Deficiency (PID) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-595 in Primary Immune Deficiency (PID) Drug Details: Human...
-
Product Insights
Likelihood of Approval Analysis for Hemophilia
Overview How likely is it that the drugs in Hemophilia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hemophilia Overview Hemophilia, a bleeding disorder affecting blood clotting, leads to prolonged bleeding...
-
Product Insights
Likelihood of Approval Analysis for Hemophilia B (Factor IX Deficiency)
Overview How likely is it that the drugs in Hemophilia B (Factor IX Deficiency) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hemophilia B (Factor IX Deficiency) Overview Hemophilia B is...
-
Product Insights
Likelihood of Approval Analysis for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Overview How likely is it that the drugs in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview Idiopathic...